<?xml version="1.0" encoding="UTF-8"?>
<p id="par0080">Starting from December 2019, a pandemic of respiratory illness caused by a novel coronavirus named SARS-CoV-2 is sweeping the mainland of China. This virus has spread to several foreign countries, threatening to trigger a global outbreak. Several antiviral agents can be envisaged to control or prevent viral infections by antiviral assay in vitro [
 <xref rid="bib0070" ref-type="bibr">14</xref>,
 <xref rid="bib0085" ref-type="bibr">17</xref>]. However, the efficacy and safety of novel candidates need validations in vivo, even for those clinically approved medicines, which means that it will take months to years for clinical practices. At present, symptomatic and supportive treatments remain key to clinical practices. Thus, Traditional Chinese Medicines (TCM) carried both the antiviral effect and the symptomatic relief might bring more clinical benefits [
 <xref rid="bib0060" ref-type="bibr">12</xref>]. As a classical TCM prescription for respiratory diseases, LH is the only approved medicine in the treatment of SARS and influenza. After the outbreak of SARS-CoV-2, LH as a representative TCM prescription was recommended again in the latest Guideline for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Pneumonia issued by National Health Commission of the Peopleâ€™s Republic of China The purpose of this study was to demonstrate whether the therapeutic effects of LH on the COVID-19 targeting virus replication and immunological regulation as it did on the infection caused by influenza viruses.
</p>
